Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

55.95USD
29 Mar 2017
Change (% chg)

$-0.25 (-0.44%)
Prev Close
$56.20
Open
$56.17
Day's High
$56.55
Day's Low
$55.93
Volume
2,087,784
Avg. Vol
2,978,509
52-wk High
$77.10
52-wk Low
$46.01

BMY.N

Chart for BMY.N

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $92,177.64
Shares Outstanding(Mil.): 1,647.50
Dividend: 0.39
Yield (%): 2.79

Financials

  BMY.N Industry Sector
P/E (TTM): 21.06 29.37 30.15
EPS (TTM): 2.66 -- --
ROI: 18.67 13.51 13.05
ROE: 29.28 14.42 14.20

BRIEF-Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo

* Bristol-Myers Squibb receives positive chmp opinion recommending opdivo (nivolumab) for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy

Mar 24 2017

BRIEF-Bristol-Myers' CEO Caforio's 2016 total compensation $16.9 mln

* Bristol-Myers Squibb Co - CEO Giovanni Caforio, M.D.'s 2016 total compensation was $16.9 million versus $15.6 million in 2015 - SEC filing

Mar 23 2017

BRIEF-Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration

* Bristol-Myers Squibb and Cytomx Therapeutics extend worldwide collaboration to discover Probody Therapeutics for the treatment of cancer and other diseases

Mar 20 2017

BRIEF-Bristol-Myers Squibb appoints Thomas Lynch as Chief Scientific Officer

* Bristol-Myers Squibb appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer

Mar 08 2017

BRIEF-Bristol-Myers Squibb declared a qtrly div of $0.39 per share

* Bristol-Myers Squibb - declared a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation Source text for Eikon: Further company coverage:

Mar 02 2017

BRIEF-Bristol-Myers announces equity investment in GRAIL Inc

* Bristol-Myers Squibb expands focus on precision medicine with investment and planned collaboration with GRAIL on blood-based cancer screening

Mar 01 2017

BRIEF-Bristol-Myers Squibb expands international immuno-oncology network

* Bristol-Myers Squibb expands international immuno-oncology network (II-ON) with addition of Columbia University Medical Center and Peter Maccallum Cancer Centre Source text for Eikon: Further company coverage:

Feb 27 2017

BRIEF-Bristol-Myers Squibb prices $1.5 billion of senior notes

* Bristol-Myers Squibb prices $1.5 billion of senior notes Source text for Eikon: Further company coverage:

Feb 22 2017

BRIEF-Bristol-Myers squibb files pricing term sheet

* Files pricing term sheet related to its offering of 2019 notes and 2027 notes - SEC filing Source text: (http://bit.ly/2lHhR1j) Further company coverage:

Feb 22 2017

Fitch Rates Bristol-Myers Squibb's Notes Offering 'A-'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, February 22 (Fitch) Fitch Ratings has assigned an 'A-' rating to Bristol-Myers Squibb Company's (Bristol, BMY) senior unsecured notes offering. Proceeds will be used to partially fund an accelerated share repurchase program (ASR). The Rating Outlook is Stable. KEY RATING DRIVERS --The company maintains decent headroom under the 2.0x gross leverage level Fitch considers appropriate for the 'A-' rating after incorporating th

Feb 22 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.92 -0.74
Pfizer Inc. (PFE.N) $34.33 +0.17
Merck & Co., Inc. (MRK.N) $63.64 +0.30
Sanofi SA (SASY.PA) €83.87 -0.64
AstraZeneca plc (AZN.L) 4,949.50 -5.00
GlaxoSmithKline plc (GSK.L) 1,682.50 +4.00
Eli Lilly and Co (LLY.N) $84.44 -0.31
Roche Holding Ltd. (ROG.S) CHF255.90 +0.50
Roche Holding Ltd. (RO.S) CHF255.25 +0.50

Earnings vs. Estimates